Eli Casdin co-leads $250M infusion into microfluidics player that landed NIH funding for Covid-19 testing
In about 17 months, Fluidigm has gone from working with sharks to Vikings.
The South San Francisco-based company, which landed NIH money in a Shark Tank-style program for Covid-19 testing, announced that it will take on an investment worth $250 million from Casdin Capital and Viking Global Investors. It will also rebrand, and call itself Standard BioTools. The investment will help the company focus on the highest growth areas of discovery and development and expand its CRO and CMO service providers. Right now, the company’s customer reach is limited to basic research, it said.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 151,300+ biopharma pros reading Endpoints daily — and it's free.